Somewhat Favorable News Coverage Somewhat Unlikely to Impact Second Sight Medical Products (EYES) Stock Price

Media stories about Second Sight Medical Products (NASDAQ:EYES) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Second Sight Medical Products earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news articles about the medical device company an impact score of 47.0752039232516 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment’s rankings:

EYES has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. HC Wainwright set a $5.00 price target on shares of Second Sight Medical Products and gave the stock a “buy” rating in a research report on Monday, February 5th.

Second Sight Medical Products (NASDAQ EYES) traded up $0.01 on Thursday, reaching $1.93. 50,799 shares of the company’s stock traded hands, compared to its average volume of 735,731. Second Sight Medical Products has a fifty-two week low of $0.90 and a fifty-two week high of $2.58. The company has a market capitalization of $109.07, a P/E ratio of -3.66 and a beta of 3.46.

Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings results on Wednesday, March 7th. The medical device company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Second Sight Medical Products had a negative net margin of 358.06% and a negative return on equity of 169.01%. The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $1.98 million. During the same period last year, the firm earned ($0.24) earnings per share. The company’s quarterly revenue was up 333.6% on a year-over-year basis. analysts predict that Second Sight Medical Products will post -0.58 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Second Sight Medical Products (EYES) Stock Price” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at

About Second Sight Medical Products

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with's FREE daily email newsletter.

Leave a Reply